EU drug watchdog to weigh in on extended use for remdesivir by summer

  • In US
  • 2021-02-23 09:22:08Z
  • By Reuters

(Reuters) - Europe's drugs regulator said on Tuesday it was expecting to give an opinion before the summer on whether Gilead Sciences' remdesivir can be used to treat COVID-19 patients who do not need oxygen support.

The indication for extended use, if approved, would allow the antiviral treatment to be given to more patients as coronavirus infections surge and healthcare systems are pressured by emerging, highly transmissible variants of the virus.

U.S.-based developer Gilead has submitted data to the European Medicines Agency (EMA), the watchdog said, adding that its human medicines committee had started evaluating the latest submissions. (

The European Union had conditionally approved remdesivir, the first COVID-19 therapy on the continent, in July last year for treating COVID-19 in adults and adolescents over 12 years with pneumonia requiring oxygen support.

Any potential endorsements by the EMA, which have to be formally approved by the European Commission, would also help Gilead to broaden sales of a hot-selling treatment that helped boost its fourth-quarter revenue.

The U.S. drugmaker earlier this month forecast 2021 sales of up to $3 billion for remdesivir, which is sold under the brand name Veklury.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Sriraj Kalluvila and Anil D'Silva)


More Related News

Italy's Lazio region asks government to consider producing Sputnik V COVID-19 vaccine
  • US
  • 2021-03-05 11:35:54Z

Italy's central Lazio region, which includes the capital Rome, asked the national government on Friday to consider producing Russia's Sputnik V COVID-19...

What you need to know about the coronavirus right now
What you need to know about the coronavirus right now
  • US
  • 2021-03-04 11:07:10Z

Europe's medicines regulator said on Thursday it has started a review of the Sputnik V COVID-19 vaccine developed by Russia's Gamaleya Institute for possible...

Europe starts formal review of Russia
Europe starts formal review of Russia's Sputnik V COVID-19 vaccine

Europe's medicines regulator said on Thursday it had started a rolling review of Russia's Sputnik V COVID-19 vaccine, an important display of confidence in...

Europe reviewing Russia
Europe reviewing Russia's COVID-19 vaccine

The human medicines committee of the European Medicines Agency (EMA) will review data from ongoing trials of the vaccine until there is enough clinical data for approval, the regulator said. EMA's "rolling reviews" are aimed to speed up the process of approving a successful vaccine by allowing researchers to submit findings in real-time, even before final trial data is ready.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply


Top News: US